2000
DOI: 10.1097/00007890-200003150-00031
|View full text |Cite
|
Sign up to set email alerts
|

N-Acetyl-L-Cysteine for Preventing Lung Reperfusion Injury After Liver Ischemia-Reperfusion

Abstract: Lung treatment with NAC during its reperfusion with IR liver effluent prevented ALI. Lung GSH replenishment accounted for lung protection, but its content did not correlate directly with grade of protection; NAC itself seemingly afforded lung protection as well.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
51
1
1

Year Published

2001
2001
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(55 citation statements)
references
References 25 publications
2
51
1
1
Order By: Relevance
“…However, it is also used for the diseases of the lungs, liver, heart, and kidney in order to treat their toxic and ischemic injuries [22][23][24][25] .…”
Section: Discussionmentioning
confidence: 99%
“…However, it is also used for the diseases of the lungs, liver, heart, and kidney in order to treat their toxic and ischemic injuries [22][23][24][25] .…”
Section: Discussionmentioning
confidence: 99%
“…For the period of reperfusion was chosen by a time of 48 hours long considered when comparing to previous studies, because in short periods is well-known how tecidual injury occurs 4,22,23 .…”
Section: Discussionmentioning
confidence: 99%
“…Its pharmacological effects include suppression of the production of tumor necrosis factor alpha, inhibit platelet aggregation, modulation of cell activation inflammatory 18 . Thus, the hypothesis that NAC acts directly protecting the cell damage may be considered, because the properties attributed to the antioxidant NAC and inhibition of inflammatory processes of lung cells are described in studies at different times of reperfusion and with application prior or during ischemia hepátic 22,[24][25][26] .…”
Section: Discussionmentioning
confidence: 99%
“…Thus, in the second model, HSA would compete for NO released by activated macrophages, impairing pathological processes requiring high local concentrations of NO or peroxynitrite. Recent in vivo studies have shown that administration of acetylcysteine ameliorates the toxic effects of a variety of experimentally or clinically induced ischemia-reperfusion syndromes of the heart, kidney, lung and liver [2,4,45]. Some have suggested that this protective affect of acetylcysteine may be due to its ability to react with NO.…”
Section: Discussionmentioning
confidence: 99%